AtriCure - ATRC Stock Forecast, Price & News

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for AtriCure in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ATRC shares.
View ATRC analyst ratings or view top-rated stocks.

4 brokerages have issued twelve-month price objectives for AtriCure's shares. Their ATRC share price forecasts range from $50.00 to $71.00. On average, they expect the company's stock price to reach $60.17 in the next twelve months. This suggests a possible upside of 32.1% from the stock's current price.
View analysts price targets for ATRC or view top-rated stocks among Wall Street analysts.

AtriCure's stock was trading at $69.53 at the start of the year. Since then, ATRC stock has decreased by 34.5% and is now trading at $45.56.
View the best growth stocks for 2022 here.

AtriCure saw a increase in short interest during the month of November. As of November 15th, there was short interest totaling 1,320,000 shares, an increase of 9.1% from the October 31st total of 1,210,000 shares. Based on an average trading volume of 303,700 shares, the short-interest ratio is presently 4.3 days. Currently, 2.9% of the shares of the stock are short sold.
View AtriCure's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 21st 2023.
View our ATRC earnings forecast.

AtriCure, Inc. (NASDAQ:ATRC) announced its quarterly earnings results on Wednesday, November, 3rd. The medical device company reported $2.11 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.28) by $2.39. The medical device company earned $70.46 million during the quarter, compared to analyst estimates of $68.95 million. AtriCure had a negative trailing twelve-month return on equity of 12.09% and a negative net margin of 17.76%. During the same period last year, the business earned ($0.11) EPS.

AtriCure issued an update on its FY 2022 earnings guidance on Tuesday, November, 8th. The company provided earnings per share (EPS) guidance of -$1.12--$1.10 for the period, compared to the consensus estimate of -$1.10. The company issued revenue guidance of $328.00 million-$333.00 million, compared to the consensus revenue estimate of $328.61 million.

38 employees have rated AtriCure Chief Executive Officer Michael Carrel on Glassdoor.com. Michael Carrel has an approval rating of 100% among the company's employees. This puts Michael Carrel in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 93.0% of employees surveyed would recommend working at AtriCure to a friend.

Based on aggregate information from My MarketBeat watchlists, some companies that other AtriCure investors own include AbbVie (ABBV), Gilead Sciences (GILD), Amgen (AMGN), Vertex Pharmaceuticals (VRTX), Enterprise Products Partners (EPD), Abbott Laboratories (ABT), Neurocrine Biosciences (NBIX), NVIDIA (NVDA), Pfizer (PFE) and Sarepta Therapeutics (SRPT).

AtriCure trades on the NASDAQ under the ticker symbol "ATRC."

AtriCure's stock is owned by many different institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (9.23%), Alliancebernstein L.P. (8.71%), BlackRock Inc. (7.70%), Fred Alger Management LLC (5.00%), First Light Asset Management LLC (3.21%) and Macquarie Group Ltd. (2.93%). Insiders that own company stock include Angela L Wirick, Angela L Wirick, David D Jr Grumhaus, Douglas J Seith, Justin J Noznesky, Justin J Noznesky, M Andrew Wade, Mark A Collar, Mark A Collar, Michael H Carrel, Regina E Groves, Salvatore Privitera, Scott William Drake, Sven Wehrwein, Tonya Austin and Vinayak Doraiswamy.
View institutional ownership trends.

Shares of ATRC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ATRC stock can currently be purchased for approximately $45.56.

AtriCure (NASDAQ:ATRC) has a market capitalization of $2.12 billion and generates $274.33 million in revenue each year. The medical device company earns $50.20 million in net income (profit) each year or ($1.22) on an earnings per share basis.

The company employs 875 workers across the globe.

AtriCure's mailing address is 7555 INNOVATION WAY, MASON OH, 45040. The official website for the company is www.atricure.com. The medical device company can be reached via phone at (513) 755-4100, via email at lynn@gilmartinir.com, or via fax at 513-755-4567.